Category: biotech

.Along with a strong track record for recognizing diamonds in the rough, Bain Financing Daily Life Sciences (BCLS) has actually become a strong force in

.Welcome to this week’s Chutes &amp Ladders, our roundup of notable leadership hirings, firings and also retirings throughout the industry. Please send the good word–

.Bristol Myers Squibb is paying out Excellent Medicine $110 thousand upfront to create reagents for ex vivo T-cell treatments. Best, which could receive a massive

.Bristol Myers Squibb is axing another major wager coming from the Caforio age, canceling an offer for Agenus’ TIGIT bispecific antitoxin 3 years after spending

.Bristol Myers Squibb has had a whiplash change of mind on its BCMA bispecific T-cell engager, stopping (PDF) more progression months after filing to operate

.AvenCell Rehabs has actually secured $112 million in series B funds as the Novo Holdings-backed biotech finds clinical proof that it can easily generate CAR-T

.Atea Pharmaceuticals’ antiviral has actually neglected an additional COVID-19 trial, yet the biotech still holds out wish the candidate has a future in liver disease

.Pinetree Rehabs are going to aid AstraZeneca plant some trees in its pipeline with a new treaty to establish a preclinical EGFR degrader worth $forty

.AstraZeneca has actually paid CSPC Drug Group $100 million for a preclinical cardiovascular disease drug. The deal, which covers a potential competitor to an Eli

.AstraZeneca has actually discussed an early check out the functionality of its own in-house antibody-drug conjugate (ADC) modern technology, releasing phase 1 information on candidates